ASTERDM.NS Stock Analysis
AS
Avoid
Based on Eyestock quantitative analysis, ASTERDM.NS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Market cap $B
0.706
Dividend yield
29.96 %
Shares outstanding
499.51 B
Aster DM Healthcare Ltd. engages in the provision of healthcare solutions. The company is headquartered in Bangalore, Karnataka and currently employs 24,653 full-time employees. The company went IPO on 2018-02-26. The firm's segments include Hospitals, Clinics, Retail Pharmacies, and Others. The Hospitals segment comprises of hospitals and in-house pharmacies at the hospitals. The Clinics segment comprises of clinics and in-house pharmacies at the clinics. The Retail Pharmacies segment comprises standalone retail pharmacies and optical outlets. The Other segment comprises healthcare consultancy services. Its geographical segments consist of gulf corporation council (GCC) States, including United Arab Emirates, Qatar, Oman, Kingdom of Saudi Arabia, Jordan, Kuwait, Bahrain, and India. The firm's healthcare services are offered under Aster, Medcare and Access brands. The company operates over 32 hospitals, 127 clinics, 521 pharmacies (Including 255 Pharmacies in India operated by Alfaone Retail Pharmacies Private Limited under brand license from Aster), and 229 labs and patient experience centers in seven countries, including India.